top of page


Nudges in Health Care Symposium
This two-day event will provide a unique opportunity to learn and collaborate, bringing together researchers, practitioners, and policymakers to explore how behavioral science can be applied to solve real-world challenges.


Effective and Rigorous Recruitment of Older Adults Living Alone with Cognitive Impairment
Dr. Portacolone will discuss issues associated with screening, consent, recruitment, and eligibility for older adults living alone with cognitive impairment. Building on her experience, including leading a large qualitative study involving multiple interviews (n=486) with over 100 racially and ethnically diverse older adults living alone in 3 states, Dr. Portacolone will also share the protocols from the US-based Living Alone with Cognitive Impairment study.


Annual Donald and Barbara Zucker Healthy Aging Lecture: Postoperative Delirium and the Acceleration of Brain Aging: Can We Stop the Snowball?
You are invited to the inaugural Donald and Barbara Zucker Healthy Aging Lecture featuring Dr. Paul García, MD, PhD. This annual series, hosted by the Northwell Roybal Center for Personalized Trials, features leading researchers at the intersection of aging-related topics including Alzheimer Disease and related dementias and physical activity.


Call for Abstracts: UPENN CHIBE 16th Annual Behavioral Science & Health Symposium
The symposium brings together researchers, policymakers, practitioners, and industry leaders to share the latest advances in behavioral science and health, foster collaboration, and explore new ideas to improve health and healthcare. Abstract submissions are currently being accepted for symposium presentations.


NIA IMPACT Collaboratory Requests for Applications
The IMPACT Collaboratory requests applications for The James L. Rudolph Career Development Award Program and Pilot Grants Program of non-pharmacological interventions for people living with dementia (PLWD) and their care partners.


New Pathways to Early Detection and Intervention in Alzheimer’s Disease
As the Alzheimer's disease landscape rapidly evolves with new biomarker tools and FDA-approved disease-modifying therapies reshaping how we diagnose and treat, earlier identification and timely intervention have never been more critical to patient outcomes. This session will review early detection approaches using clinical assessments with the latest biomarker tools, discuss appropriate patient selection and use of disease-modifying therapies.
bottom of page
